# Effect Of GW501516X On How The Heart Obtains And Uses Energy

> **NCT00318617** · — · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 30 (—)

## Conditions studied

- Dyslipidaemias
- Heart Failure

## Interventions

- **DRUG:** GW510516X

## Key facts

- **NCT ID:** NCT00318617
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2005-12
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 30 (—)
- **Last updated:** 2012-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00318617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00318617, "Effect Of GW501516X On How The Heart Obtains And Uses Energy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00318617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*